Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 8/20 | 0.35 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | POLA1 | P09884 | 1/20 | 0.33 |
| ▸ | POLD1 | P28340 | 1/20 | 0.33 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.31 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.30 |
| ▸ | POLG | P54098 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18290483 | 0.76 | POLB (0.33) | P2RY6P2RY2POLBPOLA1POLD1 | |
| SCHEMBL18290460 | 0.74 | LMNA (0.33) | — | |
| SCHEMBL16299256 | 0.71 | POLB (0.43) | P2RY6P2RY2POLBPOLA1POLD1 | |
| SCHEMBL17211005 | 0.70 | P2RY6 (0.68) | P2RY6P2RY2P2RY4 | |
| SCHEMBL14853757 | 0.70 | P2RY6 (0.68) | P2RY6P2RY2P2RY4 | |
| SCHEMBL14930962 | 0.70 | P2RY6 (0.68) | P2RY6P2RY2P2RY4 | |
| SCHEMBL15810853 | 0.70 | POLB (0.56) | POLBPOLA1POLD1 | |
| SCHEMBL16224817 | 0.66 | P2RY2 (0.42) | P2RY6P2RY2POLA1ENPP1P2RY4 | |
| SCHEMBL16575821 | 0.65 | P2RY2 (0.34) | P2RY6P2RY2POLBPOLA1POLD1 | |
| SCHEMBL25580928 | 0.64 | P2RY2 (0.45) | P2RY6P2RY2POLA1ENPP1P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160354491-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160354491-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | P2RY6 1545/4885P2RY2 2899/4885POLB 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.